Therapie, maintrac, ,CETC, Tumorzellen, Eigenschaften, Zellen, Erfolgskontrolle,

The maintrac® method detects, identifies and characterises circulating tumour cells in the blood. 15ml EDTA blood is required for this. Using antibodies, maintrac® detects the tumour cells quantitatively with the aid of a semi-automated fluorescence microscope.

This provides fast, objective analyses of the number and characteristics of suspected tumour cells in the blood. Therapeutically-relevant surface characteristics, expression profiles and gene alterations in these cells can be investigated in detail.



Cells can be released before or during surgery on a tumour. It is assumed that these are responsible for the development of metastases. The adjuvant chemotherapy should destroy these cells that remain in the body.

In spite of this treatment, 20–25% of breast cancer patients develop distant metastases within the first 5 years. Evidently, the treatment has not been effective enough in the case of these patients. It is unclear which patients actually benefit from chemotherapy.


maintrac® uses the CETCs/CTCs remaining in the body to monitor the success of the chemotherapy.

Mit maintrac®allows the response behaviour to different therapeutic measures to be monitored in real time, as there is a highly-significant correlation between the development of the cell count and the tumour activity.
  • Patients whose CETCs/CTCs are significantly reduced or eliminated have significantly higher chances of remaining relapse-free.
  • If response to a therapy is good, a decrease in the CETCs/CTCs should be detected.
  • Even after an initial response, an increase during the course of a therapy may indicate that tumour cells are still active.



Mit maintrac® allows testing of the cytotoxic effect of drugs on the CETCs directly.

The CETCs are exposed to different concentrations of the substances to be tested in vitro. The death rate of the CETCs is calculated at different times in comparison with a sample that does not have any active agent. In this way, maintrac identifies® the therapeutic agents that have the highest probability of being effective individually.

The degree of effectiveness of the drugs administered varies from patient to patient.




maintrac® in future, a blood sample is enough to carry out such an investigation on CETCs. Especially in the later stages of the disease, therapeutically-relevant characteristics of the tumour cells can change. Thus, changes due to the therapy and recurring tumour activity due to mutations, for example, can be recorded.
These changes can be monitored in the CETCs (e.g. the expression of hormone receptors or EGFR and HER2/neu gene alterations).




Therapie, maintrac, ,CETC, Tumorzellen, Eigenschaften, Zellen, Erfolgskontrolle,
Therapie, maintrac, ,CETC, Tumorzellen, Eigenschaften, Zellen, Erfolgskontrolle,

Long-term anti-hormonal therapy has particular significance in adjuvant therapy. Here, continuous monitoring over years can significantly contribute to the early detection of recurrences.

A decrease or increase in circulating epithelial cells during hormone therapy is prognostically relevant in evaluating the success of the therapy. If necessary, a change in the therapy may be introduced in good time.




Akzeptieren Durch die weitere Nutzung der Seite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen